A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : HCC / hepatocellular carcinoma

[Related PubMed/MEDLINE]
Total Number of Papers: 49244
[Display Entries]
100 entries :
     (Publication year, Descending)
100 entries :
     (Publication year, Ascending)
>> all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   HCC  (>> Co-occurring Abbreviation)
Long Form:   hepatocellular carcinoma
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2021 Clinical Utility of Mac-2 Binding Protein Glycosylation Isomer in Chronic Liver Diseases. M2BPGi, NAFLD, SVR
2021 Current treatment paradigms and emerging therapies for NAFLD/NASH. NAFLD, NASH
2021 Targeted Next-Generation Sequencing of Plasma Cell-Free DNA in Korean Patients with Hepatocellular Carcinoma. cfDNA
2020 "Inside-out" or "Outside-in": Choosing the right model of Hepatocellular Cancer. ---
2020 "Logic-Based Medicine" Is More Feasible than "Evidence-Based Medicine" in the Local Treatment for Hepatocellular Carcinoma. RFA, TBF
2020 "Perioperative Presentation of COVID-19 Disease in a Liver Transplant Recipient". LT
2020 "Six-and-twelve" score for outcome prediction of hepatocellular carcinoma following transarterial chemoembolization. In-depth analysis from a multicenter French cohort. HKLC, TACE
2020 1,8-Cineole promotes G0/G1 cell cycle arrest and oxidative stress-induced senescence in HepG2 cells and sensitizes cells to anti-senescence drugs. FC, ROS, WB
2020 125I Irradiation Stent for Hepatocellular Carcinoma with Main Portal Vein Tumor Thrombosis: A Systematic Review. MPVTT
10  2020 13-lncRNAs Signature to Improve Diagnostic and Prognostic Prediction of Hepatocellular Carcinoma. DElncRNAs, lncRNAs, ROC
11  2020 14-CpG-Based Signature Improves the Prognosis Prediction of Hepatocellular Carcinoma Patients. GEO
12  2020 18F-fluorodeoxyglucose PET/CT as an independent predictor for patients with hepatocellular carcinoma combined with major portal vein tumor thrombus. 18F-FDG, MPVTT, OS, RFS
13  2020 18F-Fluorodeoxyglucose Uptake in Hepatocellular Carcinoma as a Useful Predictor of an Extremely Rapid Response to Lenvatinib. TLR
14  2020 1H NMR-Based Metabolic Profiles Delineate the Anticancer Effect of Vitamin C and Oxaliplatin on Hepatocellular Carcinoma Cells. OXA, VC
15  2020 1H-NMR Based Serum Metabolomics Highlights Different Specific Biomarkers between Early and Advanced Hepatocellular Carcinoma Stages. OPLS-DA, OS
16  2020 1H-NMR spectroscopy metabonomics of reactive, ovarian carcinoma and hepatocellular carcinoma ascites. bAEs, HGSOC, mAE
17  2020 2,5-dimethylcelecoxib improves immune microenvironment of hepatocellular carcinoma by promoting ubiquitination of HBx-induced PD-L1. DMC, HBV, HBx, mPGES-1, PD-1
18  2020 2-O-Methylmagnolol, a Magnolol Derivative, Suppresses Hepatocellular Carcinoma Progression via Inhibiting Class I Histone Deacetylase Expression. ---
19  2020 2019 Chinese clinical guidelines for the management of hepatocellular carcinoma: updates and insights. AASLD, BCLC, CNLC, EASL, HBV, ICIs, TACE
20  2020 2019 Update of Indian National Association for Study of the LiverConsensus on Prevention, Diagnosis, and Management of Hepatocellular Carcinoma in India: The Puri II Recommendations. INASL
21  2020 2020 Taiwan consensus statement on the management of hepatitis C: Part (II) special populations. DAA, HBV, HCV, HIV, PWID, TASL
22  2020 25-OH-vitamin D deficiency identifies poor tumor response in hepatocellular carcinoma treated with transarterial chemoembolization. ROC, TACE
23  2020 3-Bromopyruvate regulates the status of glycolysis and BCNU sensitivity in human hepatocellular carcinoma cells. 3-BrPA, BCNU, CENUs, HKII, ICLs, MGMT
24  2020 32A9, a novel human antibody for designing an immunotoxin and CAR-T cells against glypican-3 in hepatocellular carcinoma. CAR-T, GPC3
25  2020 3D visualization ablation planning system assisted microwave ablation for hepatocellular carcinoma (Diameter >3): a precise clinical application. LTP, OS, RFS, US-PMWA
26  2020 4,4'‑Bond secalonic acid D targets SP cells and inhibits metastasis in hepatocellular carcinoma. CSCs, SP
27  2020 4-1BB Delineates Distinct Activation Status of Exhausted Tumor-Infiltrating CD8+ T Cells in Hepatocellular Carcinoma. PD-1, TILs
28  2020 4-Acetylantrocamol LT3, a New Ubiquinone from Antrodia cinnamomea, Inhibits Hepatocellular Carcinoma HepG2 Cell Growth by Targeting YAP/TAZ, mTOR, and WNT/beta-Catenin Signaling. AMPK, mTOR, TAZ, YAP
29  2020 4E-BP1Thr46 Phosphorylation Association with Poor Prognosis in Quantitative Phosphoproteomics of Portal Vein Tumor Thrombus Revealed that 4E-BP1Thr46 Phosphorylation is Associated with Poor Prognosis in HCC. iTRAQ, PVTT
30  2020 6H2L, a novel synthetic derivative of bifendate, induces apoptosis in hepatoma cells via mitochondrial and MAPK pathway. MAPK, WBC
31  2020 7-Methoxy-1-Tetralone Induces Apoptosis, Suppresses Cell Proliferation and Migration in Hepatocellular Carcinoma via Regulating c-Met, p-AKT, NF-kappaB, MMP2, and MMP9 Expression. MMP2, MT, p-AKT
32  2020 A "one stop liver shop" approach improves the cascade-of-care for Aboriginal and Torres Strait Islander Australians living with chronic hepatitis B in the Northern Territory of Australia: results of a novel care delivery model. AFP, CHB, HBsAg, LFT, NT, USS, VL
33  2020 A biodegradable multifunctional porous microsphere composed of carrageenan for promoting imageable trans-arterial chemoembolization. BMPMs, DOX, DSA, iTACE, MRI, SPIO, TACE
34  2020 A Biomimetic Model for Liver Cancer to Study Tumor-Stroma Interactions in a 3D Environment with Tunable Bio-Physical Properties. ---
35  2020 A blood-based 22-gene expression signature for hepatocellular carcinoma identification. AFP, LC, SVM, US
36  2020 A case of advanced HCC treated with lenvatinib after hepatic arterial infusion chemotherapy combined with radiation therapy treatment for portal vein tumor thrombosis in the main trunk. CT, DEB-TACE, HAIC, PVTT
37  2020 A case of hemorrhage of hepatocellular carcinoma resembling a hepatic cyst arising from non-cirrhotic steatohepatitis. CT, MRI
38  2020 A case of reactive lymphoid hyperplasia of the liver in a patient with autoimmune hepatitis. AIH, CT, MRI, RLH, T1WI, T2WI, US
39  2020 A case of small hepatocellular carcinoma with malignant ductular reaction. BD, CSC, DH, FS, IHC
40  2020 A case of small well-differentiated hepatocellular carcinoma with marked lymphocytic infiltrate. LF, PT, SLI, SMA
41  2020 A case report of Fontan procedure-related hepatocellular carcinoma: pure laparoscopic approach by low and stable pneumoperitoneum. CT
42  2020 A case report of granulocyte colony-stimulating factor-producing hepatocellular carcinoma that recurred after long-term complete response. G-CSF
43  2020 A Case-Control Study of ADCY9 Gene Polymorphisms and the Risk of Hepatocellular Carcinoma in the Chinese Han Population. ADCY9, FDR, SNPs
44  2020 A Case-Control Study on the Correlation Between Thymidylate Synthase Gene Polymorphisms and Raltitrexed Treatment Combined with Transcatheter Arterial Chemoembolization in Hepatocellular Carcinoma Treatment. DCR, RR, SNPs, TACE, TYMS
45  2020 A Changing Paradigm for the Treatment of Intermediate-Stage Hepatocellular Carcinoma: Asia-Pacific Primary Liver Cancer Expert Consensus Statements. APPLE, cTACE, OR, TACE
46  2020 A Cholecystokinin Receptor Antagonist Halts Nonalcoholic Steatohepatitis and Prevents Hepatocellular Carcinoma. CCK, CCKRs, CDE, NASH
47  2020 A Circulating Long Noncoding RNA Panel Serves as a Diagnostic Marker for Hepatocellular Carcinoma. AUC, lncRNAs, ROC
48  2020 A classification based on tumor budding and immune score for patients with hepatocellular carcinoma. IS-TB type
49  2020 A clinical trial with valproic acid and hydralazine in combination with gemcitabine and cisplatin followed by doxorubicin and dacarbazine for advanced hepatocellular carcinoma. HZ, OS, PFS, RR, VA
50  2020 A combination of alpha-fetoprotein, midkine, thioredoxin and a metabolite for predicting hepatocellular carcinoma. AFP, AUC, GC-MS
51  2020 A combination of AZD5363 and FH5363 induces lethal autophagy in transformed hepatocytes. THH
52  2020 A combination of the preoperative neutrophil-to-lymphocyte and lymphocyte-to-monocyte ratios as a useful predictor of survival outcomes following the transarterial chemoembolization of huge hepatocellular carcinoma. LMR, NLR, OS, ROC, TACE
53  2020 A Comparative Investigation of the Ability of Various Aptamer-Functionalized Drug Nanocarriers to Induce Selective Apoptosis in Neoplastic Hepatocytes: In Vitro and In Vivo Outcome. ---
54  2020 A comparative study of monoexponential versus biexponential models of diffusion-weighted imaging in differentiating histologic grades of hepatitis B virus-related hepatocellular carcinoma. ADC, HBV
55  2020 A Comparison of Biannual Two-Phase Low-Dose Liver CT and US for HCC Surveillance in a Group at High Risk of HCC Development. LDCT, US
56  2020 A comparison of prognoses between surgical resection and radiofrequency ablation therapy for patients with hepatocellular carcinoma and esophagogastric varices. EGV, OS, RFA, SR
57  2020 A comparison of the outcomes between surgical resection and proton beam therapy for single primary hepatocellular carcinoma. PBT, RFS, SR
58  2020 A comparison of transcatheter arterial chemoembolization used with and without apatinib for intermediate- to advanced-stage hepatocellular carcinoma: a systematic review and meta-analysis. CBM, CI, CNKI, OR, TACE, VEGFR2-TKI
59  2020 A comprehensive analysis of the MAGE family as prognostic and diagnostic markers for hepatocellular carcinoma. MAGE
60  2020 A comprehensive evaluation of single nucleotide polymorphisms associated with hepatocellular carcinoma risk in Asian populations: A systematic review and network meta-analysis. CIs, FPRP, ORs, SNPs
61  2020 A concise review of the changing landscape of hepatocellular carcinoma. ---
62  2020 A Concise Review on Current Trends in Imaging and Surgical Management of Hepatocellular Carcinoma. CT, FC, HR, LRV, LT, MRI, USS
63  2020 A Concise Review on the Frequency, Major Risk Factors and Surveillance of Hepatocellular Carcinoma (HCC) in beta-Thalassemias: Past, Present and Future Perspectives and the ICET-A Experience. CHB, CHC
64  2020 A cost analysis of SIR-Spheres yttrium-90 resin microspheres versus tyrosine kinase inhibitors in the treatment of unresectable hepatocellular carcinoma in France, Italy, Spain and the UK. BCLC, PFS, SIRT, TKIs, UK
65  2020 A CT-based radiomics nomogram for differentiation of focal nodular hyperplasia from hepatocellular carcinoma in the non-cirrhotic liver. AUC, CI, FNH, Rad-score
66  2020 A Cyclin D1-Specific Single-Chain Variable Fragment Antibody that Inhibits HepG2 Cell Growth and Proliferation. ER, Rb, scFv
67  2020 A descriptive study of racial inequalities in mortality from hepatocellular cancer before and after licensure of lifesaving drugs for hepatitis C virus in the United States. HCV, US, WONDER
68  2020 A Diamine-PEGylated Oleanolic Acid Derivative Induced Efficient Apoptosis through a Death Receptor and Mitochondrial Apoptotic Pathway in HepG2 Human Hepatoma Cells. JNK, MMP
69  2020 A differential risk assessment and decision model for Transarterial chemoembolization in hepatocellular carcinoma based on hepatic function. ALBI, CI, OS, TACE
70  2020 A Discovery of Clinically Approved Formula FBRP for Repositioning to Treat HCC by Inhibiting PI3K/AKT/NF-kappaB Activation. FBRP, NF-kappaB, PI3K
71  2020 A Disintegrin and Metalloproteinase 9 (ADAM9) in Advanced Hepatocellular Carcinoma and Their Role as a Biomarker During Hepatocellular Carcinoma Immunotherapy. ADAM9, MICA, NK
72  2020 A distinctive protein signature induced by lysophosphatidic acid receptor 6 (LPAR6) expression in hepatocellular carcinoma cells. LPAR, LPAR6
73  2020 A fat containing combined neuroendocrine carcinoma and hepatocellular carcinoma in the liver: A case report. NEC
74  2020 A FITM1-Related Methylation Signature Predicts the Prognosis of Patients With Non-Viral Hepatocellular Carcinoma. FITM1, IHC, MDGs, OS
75  2020 A fluorescent probe for monitoring PTP-PEST enzymatic activity. ---
76  2020 A four-long noncoding RNA signature predicts survival of hepatocellular carcinoma patients. CI, lncRNAs
77  2020 A Four-Methylated lncRNAs-Based Prognostic Signature for Hepatocellular Carcinoma. CCLE, lncRNAs, MDELs, OS, ROC
78  2020 A genetic variant in the promoter of CD46 is associated with the risk and prognosis of hepatocellular carcinoma. CI, OR, tagSNPs
79  2020 A genetic variant in the promoter region of miR-877 is associated with an increased risk of hepatocellular carcinoma. ---
80  2020 A glycolysis-related gene pairs signature predicts prognosis in patients with hepatocellular carcinoma. GRGPs
81  2020 A Hepatocellular Carcinoma Targeting Nanostrategy with Hypoxia-Ameliorating and Photothermal Abilities that, Combined with Immunotherapy, Inhibits Metastasis and Recurrence. Cy, NP, PB, PD-L1, SF
82  2020 A hepatocyte differentiation model reveals two subtypes of liver cancer with different oncofetal properties and therapeutic targets. ---
83  2020 A hMTR4-PDIA3P1-miR-125/124-TRAF6 Regulatory Axis and Its Function in NF kappa B Signaling and Chemoresistance. DOX, hMTR4, IkappaBalpha, lncRNAs, NF-kappaB, TRAF6
84  2020 A hypoxia-related signature for clinically predicting diagnosis, prognosis and immune microenvironment of hepatocellular carcinoma patients. DEGs, GEO, GSEA, ICGC, OS
85  2020 A Lactose-Derived CRISPR/Cas9 Delivery System for Efficient Genome Editing In Vivo to Treat Orthotopic Hepatocellular Carcinoma. LBP
86  2020 A Lamping U-Shaped Fiber Biosensor Detector for MicroRNA. ---
87  2020 A large real-world cohort study examining the effects of long-term entecavir on hepatocellular carcinoma and HBsAg seroclearance. SIR
88  2020 A magnetic SERS immunosensor for highly sensitive and selective detection of human carboxylesterase 1 in human serum samples. 4-MBA, hCE1, SERS
89  2020 A meta-analysis of the added value of diffusion weighted imaging in combination with contrast-enhanced magnetic resonance imaging for the diagnosis of small hepatocellular carcinoma lesser or equal to 2 cm. DWI, MRI
90  2020 A meta-analysis of the prognostic significance of Golgi protein 73 in hepatocellular carcinoma in Chinese patients. CI, DFS, GP73, HRs, ORs, OS
91  2020 A method to establish a c-Myc transgenic mouse model of hepatocellular carcinoma. ALB
92  2020 A micro-elimination approach to addressing hepatitis C in Turkey. GHSS
93  2020 A mixed-methods approach to understanding perceptions of hepatitis B and hepatocellular carcinoma among ethnically diverse Black communities in South Florida. ---
94  2020 A model based on non-invasive markers predicts very low hepatocellular carcinoma risk after viral response in HCV-advanced fibrosis. EOT, SVR, TE
95  2020 A Modified Protocol of Diethylnitrosamine Administration in Mice to Model Hepatocellular Carcinoma. DEN, TAA
96  2020 A Molecular Subtype Model for Liver HBV-Related Hepatocellular Carcinoma Patients Based on Immune-Related Genes. HBV
97  2020 A multi-center study of trends in hepatitis B virus-related hepatocellular carcinoma risk over time during long-term entecavir therapy. aHR, CHB, HBV
98  2020 A Multi-Institutional Retrospective Study of Repeated Stereotactic Body Radiation Therapy for Intrahepatic Recurrent Hepatocellular Carcinoma. CI, OS, SBRT
99  2020 A Multi-Omics Approach to Liver Diseases: Integration of Single Nuclei Transcriptomics with Proteomics and HiCap Bulk Data in Human Liver. snRNA-seq
100  2020 A Multicenter Phase II Study of Second-Line Axitinib for Patients with Advanced Hepatocellular Carcinoma Failing First-Line Sorafenib Monotherapy. OS, PFS